AU2021281256A1 - PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders - Google Patents

PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders Download PDF

Info

Publication number
AU2021281256A1
AU2021281256A1 AU2021281256A AU2021281256A AU2021281256A1 AU 2021281256 A1 AU2021281256 A1 AU 2021281256A1 AU 2021281256 A AU2021281256 A AU 2021281256A AU 2021281256 A AU2021281256 A AU 2021281256A AU 2021281256 A1 AU2021281256 A1 AU 2021281256A1
Authority
AU
Australia
Prior art keywords
ldl
subject
pcsk9
inhibitor
hefh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021281256A
Other languages
English (en)
Inventor
Ian Matthew BRIDGES
Andrew W. HAMER
Christopher KURTZ
Andrea RUZZA
Huei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2021281256A1 publication Critical patent/AU2021281256A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2021281256A 2020-05-29 2021-05-27 PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders Pending AU2021281256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
US63/032,451 2020-05-29
PCT/US2021/034489 WO2021243002A1 (en) 2020-05-29 2021-05-27 Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Publications (1)

Publication Number Publication Date
AU2021281256A1 true AU2021281256A1 (en) 2022-12-22

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021281256A Pending AU2021281256A1 (en) 2020-05-29 2021-05-27 PCSK9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Country Status (11)

Country Link
US (1) US20230235085A1 (https=)
EP (1) EP4157887A4 (https=)
JP (1) JP2023527542A (https=)
CN (1) CN115916838A (https=)
AR (1) AR122180A1 (https=)
AU (1) AU2021281256A1 (https=)
CA (1) CA3179316A1 (https=)
IL (1) IL298375A (https=)
JO (1) JOP20220322A1 (https=)
TW (1) TW202210524A (https=)
WO (1) WO2021243002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121693519A (zh) 2023-08-14 2026-03-17 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)

Also Published As

Publication number Publication date
WO2021243002A1 (en) 2021-12-02
IL298375A (en) 2023-01-01
TW202210524A (zh) 2022-03-16
JP2023527542A (ja) 2023-06-29
CA3179316A1 (en) 2021-12-02
EP4157887A1 (en) 2023-04-05
US20230235085A1 (en) 2023-07-27
CN115916838A (zh) 2023-04-04
JOP20220322A1 (ar) 2022-11-27
AR122180A1 (es) 2022-08-24
EP4157887A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
US12331122B2 (en) Anti-ASGR-1 monoclonal inhibitory antibodies
US20230235085A1 (en) Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
JP4898976B2 (ja) Ｐｃｓｋ９拮抗薬
US20230117883A1 (en) Muscle-targeting complexes and uses thereof in treating muscle atrophy
JP7847090B2 (ja) 操作されたｂ型肝炎ウイルス中和抗体およびその使用
JP7783840B2 (ja) 抗ｃｔｌａ－４結合タンパク質及びその使用方法
WO2021253002A1 (en) Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
CA2779683A1 (en) Anti-c-mpl antibodies
HK40090853A (zh) Pcsk9抑制剂及其用於治疗胆固醇相关障碍的方法
US20250289903A1 (en) Methods and compositions for treating eosinophil driven diseases and disorders
TW202323300A (zh) 抗tigit構築體及其用途
KR20240019073A (ko) Nkp46 및 gpc3를 표적으로 하는 이중 특이적 항체 및 이의 사용 방법